# 1 The impact of high frequency rapid viral antigen screening on COVID-19 spread 2 and outcomes: a validation and modeling study

- 3
- 4 Authors: Beatrice Nash<sup>1,2\*</sup>, Anthony Badea<sup>1,3\*</sup>, Ankita Reddy<sup>1,4\*</sup>, Miguel Bosch<sup>1,5</sup>, Nol
- 5 Salcedo<sup>1</sup>, Adam R. Gomez<sup>1</sup>, Alice Versiani<sup>6</sup>, Gislaine Celestino Dutra Silva<sup>6</sup>, Thayza
- 6 Maria Izabel Lopes dos Santos<sup>6</sup>, Bruno H. G. A. Milhim<sup>6</sup>, Marilia M. Moraes<sup>6</sup>, Guilherme
- 7 Rodrigues Fernandes Campos<sup>6</sup>, Flávia Quieroz<sup>6</sup>, Andreia Francesli Negri Reis<sup>6</sup>, Mauricio
- 8 L. Nogueira<sup>6</sup>, Elena N. Naumova<sup>7</sup>, Irene Bosch<sup>1,8</sup>, Bobby Brooke Herrera<sup>1,9‡</sup>
- 9
- 10 \*These authors contributed equally to this work.
- 11
- 12 Affiliations:
- 13 <sup>1</sup>E25Bio, Inc., Cambridge, MA, USA
- 14 <sup>2</sup>Department of Computer Science, Harvard University School of Engineering and Applied
- 15 Sciences, Cambridge, MA, USA
- <sup>3</sup>Department of Physics, Harvard University, Cambridge, MA, USA
- <sup>4</sup>Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
- 18 <sup>5</sup>InfoGeosciences LLC, Houston, TX, USA
- 19 <sup>6</sup>Faculdade de Medicina de São José do Rio Preto (FAMERP), São José do Rio Preto,
- 20 Brazil
- <sup>7</sup>Division of the Nutrition Epidemiology and Data Science, Friedman School of Nutrition
- 22 Science and Policy, Tufts University, Boston, MA, USA
- <sup>8</sup>Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA

24	<sup>9</sup> Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public
25	Health, Boston, MA, USA
26	
27	<sup>‡</sup> Corresponding Author. BBH, email: <u>bbherrera@e25bio.com</u>
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	

# 47 Abstract

48 High frequency screening of populations has been proposed as a strategy in 49 facilitating control of the COVID-19 pandemic. Here we use computational modeling, coupled with clinical data from a rapid antigen test, to predict the impact of frequent rapid 50 51 testing on COVID-19 spread and outcomes. Using patient nasopharyngeal swab 52 specimens, we demonstrate that the sensitivity and specificity of the rapid antigen test 53 compared to guantitative real-time polymerase chain reaction (gRT-PCR) are 84.7% and 54 85.7%, respectively; moreover, sensitivity correlates directly with viral load. Based on 55 COVID-19 data from three regions in the United States and São José do Rio Preto, Brazil, 56 we show that high frequency, strategic population-wide rapid testing, even at varied accuracy levels, diminishes COVID-19 infections, hospitalizations, and deaths at a 57 fraction of the cost of nucleic acid detection via gRT-PCR. We propose large-scale 58 antigen-based surveillance as a viable strategy to control SARS-CoV-2 spread and to 59 60 enable societal re-opening.

- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69

# 70 INTRODUCTION

71 The COVID-19 pandemic has taken an unprecedented toll on lives, wellbeing, 72 healthcare systems, and global economies. As of 1 September 2020, there have been more than 25.5 million confirmed cases globally with more than 850,000 confirmed 73 74 deaths<sup>1</sup>. However, these numbers and the current mapping of disease spread present an 75 incomplete picture of the outbreak largely due to the lack of adequate testing, particularly 76 as undetected infected cases are the main source of disease spread<sup>2-7</sup>. It is estimated that the reported detection rate of actual COVID-19 cases is only 1-2%<sup>5</sup>. As of September 77 78 2020, the United States and Brazil remain the top two countries with the highest number 79 of COVID-19 cases and deaths worldwide. As countries begin to re-open their economies, a method for accessible and frequent surveillance of COVID-19, with the necessary rapid 80 81 guarantine measures, is crucial to prevent the multiple resurgences of the disease.

82 The current standard of care rightfully places a strong focus on the diagnostic limit 83 of detection, yet frequently at the expense of both cost and turnaround time. This situation 84 has contributed to limited population testing largely due to a dearth of diagnostic 85 resources. Quantitative real-time polymerase chain reaction (gRT-PCR) is the gold-86 standard method for clinical diagnosis, with high sensitivity and specificity, but these tests are accompanied by the need for trained personnel, expensive reagents and 87 88 instrumentation, and a significant amount of time to execute. Facilities offering qRT-PCR 89 sometimes require a week or longer to complete and return the results to the patient. 90 During this waiting period the undiagnosed individual may spread the infection and/or 91 receive delayed medical treatment. Moreover, due to the cost and relative inaccessibility 92 of gRT-PCR in both resource-limited and abundant settings, large-scale screening using

93 qRT-PCR at frequent intervals remains impractical as a way to identify infected but
94 asymptomatic or mildly symptomatic infections. Numerous studies have reported
95 asymptomatic COVID-19 cases as well as a variation in viral load within and between
96 individuals at different time points, suggesting the need for more frequent testing for
97 informative surveillance.

98 Technologies alternate to gRT-PCR, such as rapid viral antigen detection, clustered regularly interspaced short palindromic repeats (CRISPR), and loop-mediated 99 100 isothermal amplification (LAMP) of SARS-CoV-2 provide potential large-scale screening 101 applications, yet their implementation is stymied by requirements for gRT-PCR-like accuracy before they can reach the market<sup>8</sup>. In countries such as India, where the gRT-102 103 PCR resources would not be sufficient to cover monitoring of the population, the use of 104 rapid antigen tests is well underway<sup>9,10</sup>. In early May 2020, the United States Food and 105 Drug Administration (FDA) authorized the first antigen test for the laboratory detection of 106 COVID-19, citing a need for testing beyond molecular and serological methods. Antigen 107 testing detects the viral proteins rather than nucleic acids or human antibodies, allowing 108 for detection of an active infection with relative ease of sample collection and assay. 109 These rapid assays – like other commercially-available rapid antigen tests - can be mass-110 produced at low prices and be administered by the average person without a laboratory 111 or instrumentation. These tests also take as little as 15 minutes to determine the result, 112 enabling real-time surveillance and/or diagnosis. Although antigen tests usually perform 113 with high specificities (true negative rate), their sensitivity (true positive rate) is often lower 114 when compared to molecular assays. While gRT-PCR can reach a limit of detection as

115 low as  $10^2$  genome copies per mL<sup>11</sup>, rapid antigen testing detects viral protein that is 116 assumed to correlate with approximately  $10^5$  genome copies per mL.

117 We hypothesize that frequent antigen-based rapid testing even with lower 118 sensitivities compared to gRT-PCR - along with appropriate guarantine measures - can 119 be more effective at decreasing COVID-19 spread than less frequent molecular testing of 120 symptomatic individuals. Keeping in mind the realities of daily testing in resource-limited 121 regions, we also hypothesize that testing frequency can be adjusted according to the 122 prevalence of the disease; that is, an uptick in reported cases should be accompanied by 123 more frequent testing. During the viral incubation period, peak infectivity correlates with a high viral load that can be detected by either gRT-PCR or rapid antigen testing<sup>12-15</sup>. 124 125 Rapid tests thus optimize diagnosis for the most infectious individuals. Studies also point 126 to the relatively small window of time during an individual's incubation period in which the 127 gRT-PCR assay is more sensitive than rapid tests<sup>12</sup>.

128 In this study we report the development and clinical validation of a direct antigen 129 rapid test for detection of SARS-CoV-2 spike glycoprotein using 121 retrospectively 130 collected nasopharyngeal swab specimens. Using the clinical performance data, we 131 develop a modeling system to evaluate the impact of frequent rapid testing on COVID-19 132 spread and outcomes using a variation of a SIR model, which has been previously used to model COVID-19 transmission<sup>16–22</sup>. We build on this model to incorporate guarantine 133 134 states and testing protocols to examine the effects of different testing regimes. This model 135 distinguishes between undetected and detected infections and separates severe cases, 136 specifically, those requiring hospitalization, from those less so, which is important for 137 disease response systems such as intensive care unit triaging. We simulate COVID-19

138 spread with rapid testing and model disease outcomes in three regions in the United 139 States and São José do Rio Preto, Brazil - the site of the clinical validation study - using 140 publicly available data. To date, COVID-19 modeling describes the course of disease 141 spread in response to social distancing and guarantine measures, and a previous 142 simulation study has shown that frequent testing with accuracies less than gRT-PCR, 143 coupled with guarantine process and social distancing, are predicted to significantly decrease infections<sup>12,16,22–26</sup>. This is the first modeling system using publicly-available 144 145 data to simulate how potential public health strategies based on testing performance, 146 frequency, and geography impact the course of COVID-19 spread and outcomes. Our 147 findings suggest that a rapid test, even with sensitivities lower than molecular tests, when strategically administered 2-3 times per week, will diminish COVID-19 spread, 148 149 hospitalizations, and deaths at a fraction of the cost of nucleic acid testing via qRT-PCR.

150

#### 151 **RESULTS**

#### 152 Direct Antigen Rapid Test Accuracy Correlates with Viral Load Levels

Rapid antigen tests have recently been considered a viable source for first-line screening, although concerns about the accuracy of these tests persist. We developed a direct antigen rapid test in a lateral flow dipstick format for the detection of the spike glycoprotein from SARS-CoV-2 in nasopharyngeal swab specimens. Of the total number of nasopharyngeal swab specimens evaluated by qRT-PCR for amplification of SARS-CoV-2 RNA-dependent RNA polymerase (RdRp), nucleocapsid (N), and envelope (E) genes, 72 tested positive and 49 tested negative (Table 1).

The overall sensitivity and specificity of the rapid antigen test was 84.7% and 85.7%, respectively (Table 1). Our data demonstrate that the sensitivity of our test is positively correlated to the viral load level (Fig. 1, Table 2). The rapid test result was compared to the qRT-PCR cycle threshold (Ct) value measured across RdRp, N, and E genes, and calculated as sensitivity and specificity.

165

166

**Table 1.** Clinical validation summary for the SARS-CoV-2 direct antigen rapid test (DART) evaluated using 121 retrospectively collected patient nasopharyngeal swab specimens.

167

	All Data Summary										
		•	·PCR verage)				onfidence terval				
		+	-	Total	Sensitivity	84.7%	80.6%	88.9%			
DART	+	61	7	68	Specificity	85.7%	80.8%	90.6%			
DART	- 11		42	53	Positive Predictive Value	89.7%	86.2%	93.2%			
	Total	72	49	121	Negative Predictive Value	79.2%	73.6%	84.9%			
				Prevalence	59.5%	53.9%	65.1%				
				Overall Agreement	85.1%	82.0%	88.3%				

168

169

170

171


172

173

174

**Table 2.** Data summary of direct antigen tapid test (DART) performance in comparison to qRT-PCR results; for each gene being detected and amplified by qRT-PCR (E: envelope, N: nucleocapsid, RdRp: RNA-dependent RNA polymerase, and average), DART performance is organized by qRT-PCR Cycle threshold value increments.

Agreement	86.0%	89.2%	91.1%	91.7%	85.1%	85.1%	85.7%	88.5%	91.1%	89.0%	85.8%	85.1%	87.0%	91.4%	91.2%	88.6%	85.1%	85.1%	86.3%	90.3%	91.1%	89.2%	85.1%	85.1%
Prevalence	2.0%	24.6%	45.6%	54.6%	59.5%	59.5%	%0.0	19.7%	45.6%	55.0%	59.2%	59.5%	9.3%	39.5%	46.2%	57.0%	59.5%	59.5%	3.9%	31.9%	45.6%	55.9%	59.5%	59.5%
Negative Predictive Value (NPV)	100.0%	100.0%	97.7%	95.5%	79.2%	79.2%	100.0%	100.0%	97.7%	89.4%	80.8%	79.2%	100.0%	100.0%	97.7%	87.5%	79.2%	79.2%	98.9%	98.9%	96.6%	89.4%	79.2%	79.2%
Positive Predictive Value (PPV)	12.5%	69.6%	85.1%	89.1%	89.7%	89.7%	%0'0	63.2%	85.1%	88.7%	89.7%	89.7%	41.7%	82.1%	85.4%	89.4%	89.7%	89.7%	22.2%	76.7%	85.1%	89.1%	89.7%	89.7%
95% Confidence Interval (semi- interval)	4.9%	4.9%	4.9%	4.9%	4.9%	4.9%	4.9%	4.9%	4.9%	4.9%	4.9%	4.9%	4.9%	4.9%	4.9%	4.9%	4.9%	4.9%	4.9%	4.9%	4.9%	4.9%	4.9%	4.9%
Specificity	85.7%	85.7%	85.7%	85.7%	85.7%	85.7%	85.7%	85.7%	85.7%	85.7%	85.7%	85.7%	85.7%	85.7%	85.7%	85.7%	85.7%	85.7%	85.7%	85.7%	85.7%	85.7%	85.7%	85.7%
95% Confidence Interval (semi- interval)	30.0%	3.9%	2.8%	2.5%	4.1%	4.1%		5.1%	2.8%	3.5%	4.0%	4.1%	10.8%	2.0%	2.7%	3.5%	4.1%	4.1%	20.9%	2.8%	2.8%	3.4%	4.1%	4.1%
Sensitivity	100.0%	100.0%	97.6%	96.6%	84.7%	84.7%		100.0%	97.6%	91.7%	85.9%	84.7%	100.0%	100.0%	97.6%	90.8%	84.7%	84.7%	100.0%	100.0%	97.6%	91.9%	84.7%	84.7%
Percentile Positives in Total Positive Population	98.6%	77.8%	43.1%	18.1%	2.8%	0.0%	100.0%	83.3%	43.1%	16.7%	1.4%	0.0%	93.1%	55.6%	41.7%	9.7%	0.0%	0.0%	97.2%	68.1%	43.1%	13.9%	0.0%	0.0%
DART Negatives	49	49	49	49	49	49	49	49	49	49	49	49	49	49	49	49	49	49	49	49	49	49	49	49
DART Positives	1	16	41	59	72	72	0	12	41	60	71	72	5	32	42	65	72	72	2	23	41	62	72	72
Total Cases	50	65	60	108	121	121	49	61	60	109	120	121	54	81	91	114	121	121	51	72	06	111	121	121
Cycle threshold (Ct) value	< 10	< 15	< 20	< 25	< 30	< 35	< 10	< 15	< 20	< 25	< 30	< 35	< 10	< 15	< 20	< 25	< 30	< 35	< 10	< 15	< 20	< 25	< 30	< 35
	•	əuə	ə6	dЯ	рЯ				eue 40		-	, 2.	S-VoC-28A2 9n9g E 9g819vA 9n95						อ					



**Figure 1.** Performance of direct antigen rapid test (DART) for the detection of SARS-CoV-2 in 121 retrospectively collected patient nasopharyngeal swab specimens. Percentile Positive ranks the samples in order of high Cycle threshold (Ct) value to low Ct value. DART sensitivity is determined by calculating true positive agreement to qRT-PCR; the plot uses an ax<sup>b</sup>+c fit and 95% confidence intervals for the sensitivity. Shown are the percentile positive cases of the total positive population conditioned to qRT-PCR Ct for RdRp (RNA-dependent RNA polymerase), N (nucleocapsid), and E (envelope) genes, and the average of these genes.

179

180 Ct value cutoffs represent the number of qRT-PCR cycles at which generated 181 fluorescence crosses a threshold during the linear amplification phase. The x-axis of 182 Figure 1 describes the percentile positives in the total positive population. Percentile 183 Positives ranks the samples in order of high gRT-PCR Ct value to low. In other words, 184 the higher the percentile, the more "positive" because fewer gRT-PCR cycles are required 185 for gene detection. Because the Ct value is a variable unit based upon gRT-PCR protocol 186 and instrumentation, we evaluated sensitivity against the percentile of cases across Ct 187 values.

As the percentile positive increases, the sensitivity between the rapid test and the gold-standard qRT-PCR increases, reaching 100% sensitivity at 68.1% percentile

positive for the gene average detection. Significantly, even at percentile positives between 0% and 68.1%, the sensitivity remains above 80%. Taken together, the clinical data shows that the rapid antigen test performs with increasing accuracy for individuals with a higher viral load, and are thus the most infectious<sup>13–15</sup>.


194

# 195 An Enhanced Epidemiological SIDHRE-Q Model

196 We propose an enhanced epidemiological modeling system, SIDHRE-Q, a variant 197 of the classical SIR model in order to expand our clinical validation study and to 198 understand the effects of using frequent rapid tests such as the rapid antigen test on 199 COVID-19 outbreak dynamics. The changes we make to the basic model to encompass 200 the unique characteristics of the COVID-19 pandemic are similar to those presented by 201 Giordano et al.<sup>16</sup> (Fig. 2). The differential equations governing the evolution of the 202 SIDHRE-Q model and descriptions of the parameter values are provided in the material 203 and methods section (Equation 2, Table 5).

204

205



### 207

**Figure 2.** Graphical scheme displaying the relationships between the stages of quarantine and infection in *SIDHRE*-Q model: **Q-U**, quarantine uninfected; **S**, susceptible (uninfected); **I**, infected undetected (pre-testing and infected); **D**, infected detected (infection diagnosis through testing); **H**, hospitalized (infected with life threatening symptom progression); **R**, recovered (healed); **E**, extinct (dead); and **Q-R**, quarantine recovered (healed but in quarantine by false positive testing).

**Figure Supplement 1**. Graphical scheme displaying parameters between the stages of quarantine and infection in SIDHRE-Q model.

- 208
- 209

210	An individual that begins in <b>S</b> may either transition to a Quarantine Uninfected ( <b>Q-</b>
211	U) state via a false positive result or to an Infected Undetected (I) state via interaction
212	with an infected individual. Should an individual in <b>S</b> move into <b>Q-U</b> , they are quarantined
213	for 14 days before returning to ${f S}$ , a time period chosen based on current knowledge of
214	the infectious period of the disease. One could also conceive of an effective strategy in
215	which individuals exit quarantine after producing a certain number of negative rapid tests
216	in the days following their initial positive result or confirm their negative result using qRT-
217	PCR.

218 Given that those diagnosed are predominantly guarantined, individuals in I interact 219 more with the **S** population than do those in Infected Detected (**D**). Therefore, the 220 infectious rate for I is assumed to be significantly larger than for **D**. Furthermore, a region's 221 ability to control an outbreak is directly related to how guickly and effectively people in I 222 test into **D**, reducing their infectiousness through guarantine. This study, in particular, 223 highlights the critical role frequency of testing, along with strict guarantine, has in 224 mitigating the spread of the disease and provides specific testing strategies based on 225 rapid tests we predict to be highly effective.

226 In this model, we assume that individuals receive a positive diagnosis before 227 developing severe symptoms and that those with symptoms severe enough to be 228 potentially fatal will go to the hospital. If an individual develops symptoms, we assume 229 they are tested daily until receiving a positive result; hence, before severe symptoms 230 develop, they will be diagnosed with high probability. Those who do not develop 231 symptoms are tested according to the frequency of tests administered to the general 232 population. Therefore, there is no modeled connection between I and H or between I and 233 E. Removing these assumptions would have negligible impact on the results as these 234 flows are very small.

Should an individual test positive and transition to **D**, they may either develop serious symptoms requiring care or recover. Those who develop serious symptoms and transition to state **H** will then transition to either **R** or **E**. The recovered population is inevitably tested, as infected individuals may recover without being detected. Therefore, the Quarantined Recovered (**Q-R**) state is introduced with the same connections to **R** as the connections between **S** and **Q-U**. Though the reinfection rate of SARS-CoV-2 has

been a point of recent debate, it is assumed that the number of re-infected individuals is
small<sup>27-31</sup>. Therefore, individuals cannot transition from **R** to **S**, hence the separately
categorized guarantined populations.

We considered several variations and extensions of the *SIDHRE-Q* model. In simulations, we tested additional states, such as those in the *SIDARTHE* model, which include distinctions between symptomatic and asymptomatic cases for both detected and undetected populations<sup>16</sup>. Incorporating information about the correlations between viral load and infectivity and sensitivity were also considered. Altogether, our modeling system has been well tuned to predict the impact of high frequency rapid testing on COVID-19 spread and outcomes.

251


252 Frequent Rapid Testing with Actionable Quarantining Dramatically Reduces
 253 Disease Spread

254 In order to demonstrate how strategies could affect the disease spread in different 255 geographies and demographics, we used surveillance data obtained from regions of 256 varying characteristics: the state of Massachusetts (MA), New York City (NYC), Los 257 Angeles (LA), and São José do Rio Preto (SJRP), Brazil, the site of the rapid antigen test clinical validation study. These regions are also selected in our study due to the readily 258 259 available surveillance data provided by the local governments. We fit the model to the 260 data from each region starting 1 April 2020. At this time point the disease reportedly is 261 most advanced in NYC and least advanced in SJRP, Brazil with estimated cumulative 262 infection rates of 7.11% and 0.12%, respectively.

After calibrating the *SIDHRE-Q* model, the disease spread is observed with varying validated rapid antigen test performances and frequencies (Fig. 3). Sensitivity (the ratio of true positives to the total number of positives) and specificity (the ratio of true negatives to the total number of negatives) compared to gold-standard qRT-PCR were used as measures of test accuracy.

The rapid test frequency is varied while maintaining an accuracy of 80% sensitivity and 90% specificity, comparable to our clinical data collected in SJRP, Brazil. These testing scenarios are then compared to symptomatic testing, in which individuals receive a rapid test only when presenting symptoms, via either a rapid test or qRT-PCR. Since the primary testing regiment deployed in MA, LA, NYC and SJRP, Brazil is qRT-PCRbased and focused on symptomatic individuals, the symptomatic testing protocol via qRT-PCR is directly estimated from the data to be the rate  $\nu$  (Table 5).

The difference between the qRT-PCR and rapid test simulations (red and orange lines, respectively) is therefore only sensitivity of testing (Fig. 3). We assumed that test outcome probability is a function only of whether an individual is infected and independent of other factors; one can consider this a lower bound on effectiveness of a strategy, as sensitivity and infectivity are often positively correlated with antigen testing.



Sensitivity: 80.0% Specificity: 90.0%

**Figure 3.** COVID-19 Outcomes in 3 US Regions and Brazil as a result of Frequent Rapid Testing Protocol using the *SIDHRE-Q* Model. The Cumulative Detected Infected, Hospitalized, Deceased, Active Infections, Recovered, and Quarantined are modeled over 105 days (top to bottom) using reported data from 4 global regions: Massachusetts, Los Angeles, New York City, and São José do Rio Preto in Brazil (left to right). The COVID-19 population spread and outcomes are modeled under a Rapid Testing Protocol (sensitivity 80%, specificity 90%) with variable testing frequencies ranging from 1-21 days between tests. This protocol is compared to a symptom-based Rapid Testing protocol and a symptom-based gRT-PCR protocol.

**Figure Supplement 1.** COVID-19 Outcomes as a result of Frequent Rapid Testing Protocol with variable test performances using SIDHRE-Q Model.

**Figure Supplement 2**. Time series of the four fitted parameters  $\alpha$ ,  $\nu$ ,  $\mu$ , and  $\tau$ .

281

282

To better understand the effect of rapid testing frequency and performance on healthcare capacity and mortality rates, we simulate the testing strategy with 30%-90% sensitivity each with 80% or 90% specificity against the symptomatic testing strategy. Table 3 describes the different test performances implemented in the model matched with corresponding Figure 3 - Figure Supplement 1 plots.

**Table 3**. Test Performance with corresponding Figure 3 - Figure Supplement 1 designation.

288

Sensitivity (%)	Specificity (%)	Fig. 3 Supplemental Fig.
90	90	1A
70	90	1B
50	90	1C
30	90	1D
90	80	1E
70	80	1F
50	80	1G
30	80	1H

289

291 As per our hypothesis, frequency and symptom-based testing dramatically 292 reduced infections, simultaneous hospitalizations, and total deaths when compared to the 293 purely symptom-based testing regiments, and infections, hospitalization, and death were 294 reduced as frequency increased. Although testing every day was clearly most effective, 295 even testing every fourteen days with an imperfect test gave an improvement over 296 symptomatic testing with gRT-PCR. While the strategy works best when implemented at the very beginning of an outbreak, as demonstrated by the results in SJRP, Brazil, it also 297 298 works to curb an outbreak that is already large, as demonstrated by the results in NYC. 299 The difference between frequencies is more noticeable when the testing strategy is 300 applied to the outbreak in NYC, leading us to hypothesize that smaller outbreaks require 301 a lower testing frequency than larger ones; note the difference between the dependence 302 on frequency to curb a small initial outbreak in SJRP, Brazil versus a large one in NYC 303 (Fig. 4, Figure 4 - Figure Supplement 1).

304 For test performance of 80% sensitivity and 90% specificity, the percent of the 305 population that has been infected in total from the beginning of the outbreak to mid-July 306 drops from 18% (MA), 11% (LA), 26% (NYC), and 11% (SJRP, Brazil) to 3%, 2%, 12%, 307 and 0.26%, respectively, using a weekly rapid testing and guarantine strategy (with 308 regards to predictions of overall infection rates, other studies based on seroprevalence 309 and epidemiological predictions have reached similar conclusions<sup>32,33</sup>). If testing is 310 increased to once every three days, these numbers drop further to 1.6% (MA), 1.4% (LA), 311 9.4% (NYC), and 0.19% (SJRP, Brazil) (Table 4).

312

**Table 4.** Summary of results of COVID-19 outcomes in 3 US Regions and Brazil as a result of Frequent Rapid Testing Protocol using SIDHRE-Q Model.

313

	Massac	husetts	Los A	ngeles	New Yo	ork City	São Jo Rio Pret	osé do o, Brazil
	qRT-PCR	1 per 3 days	qRT-PCR	1 per 3 days	qRT-PCR	1 per 3 days	qRT-PCR	1 per 3 days
Total Infected	18.40%	1.60%	11.70%	1.42%	26.40%	9.45%	11.70%	0.186%
Max Hospitalized	0.056%	0.025%	0.028%	0.022%	0.144%	0.130%	0.054%	0.003%
Total Deaths	0.119%	0.029%	0.039%	0.009%	0.226%	0.157%	0.040%	0.003%

314


315

316 To further examine the relationship between frequency and sensitivity, we modeled 317 the maximum number of individuals in a given state over the 105-day time period for four 318 geographic regions (Fig. 4). In all four geographic regions, as frequency of testing 319 increases, the total infections, maximum simultaneous hospitalizations, and total deaths 320 converge to small percentages regardless of the sensitivity at high frequencies. It is clear 321 that the difference in frequency required to achieve the same result using tests of differing 322 sensitivities is very small (Fig. 4) For example, we predict that for the outbreak in LA, a 323 testing strategy started on 1 April of every 10 days using a test of sensitivity 90% would have resulted in 2.5% of the population having been infected, while using a test of 324 325 sensitivity 30% would require a strategy of every 5 days to achieve the same number. 326 Thus, we conclude that frequency is more important than sensitivity in curbing the spread, 327 and a large range of sensitivities prove effective when testing sufficiently often. How 328 frequently, exactly, depends on the specific outbreak and what stage it is in, which leads 329 us to the location-based deployment strategy discussed in a later section. Frequency of

testing can be significantly reduced to effectively contain the disease once the initial
outbreak has been controlled; it is clear that this takes only a matter of weeks (Fig. 3).

332 On the other hand, according to the specificity of the rapid test and the guarantine 333 duration, larger testing frequency result in a larger percent of the population guarantined 334 (Fig. 3). Assuming a 90% rapid test specificity and 14-day guarantine duration, for the 1-335 , 3- and 7-day frequencies almost 60%, 38% and 20% of the population, respectively, 336 would be guarantined. This figure may be reduced with additional rules for exiting 337 quarantine early, such as after complementary testing. An example of such a strategy is 338 that individuals who test positive are required to either guarantine for two weeks or 339 produce two consecutive negative rapid tests in the two days following their positive 340 result. Assuming 80% sensitivity and 90% specificity, those individuals will reenter the 341 public while still infected with probability 0.04. If uninfected, that individual will exit 342 quarantine after two days with probability 0.81. However, a compromise between the 343 reduction of infections and the proportion of the population in guarantine would be part of 344 the planning for the appropriate testing protocol in each community or region.

Additionally, while high frequency may be necessary to contain a large outbreak initially, relatively infrequent testing, such as every one or two weeks, is sufficient to keep controlled outbreaks small, while reducing the number of quarantined individuals to less than 10% of the population using a two-week mandatory quarantine.



349

**Figure 4.** Effect of Rapid Testing Protocol under variable testing sensitivities and increasing frequency under the *SIDHRE-Q* Model. The Cumulative Infections, Maximum Simultaneously Hospitalized, and Deceased populations are modeled for Massachusetts, Los Angeles, New York City, and São José do Rio Preto in Brazil. The effect of increasing frequency of testing is modeled for various testing sensitivities (30%-90%) with a 90% specificity.

**Figure 4 - Figure Supplement 1**. Effect of Rapid Testing Protocol under variable testing sensitivities and increasing frequency under the *SIDHRE-Q* Model (80% specificity).

350 351				
352				
353				
354				

# A County-Based Testing Strategy Offers a Cost-effective Approach to Large-scale COVID-19 Surveillance

357 To examine the effects of resource-strategic testing schemes, we modeled the 358 COVID-19 prevalence by varying testing frequency across counties of California. For this 359 analysis, only California was analyzed because of the accessibility of the county level 360 data. In this scheme, the percent of active infected detected individuals in a county 361 determines the frequency of testing. We define thresholds for the number of active detected infections that, when hit, initiate testing protocols of different frequencies 362 363 depending on the threshold hit. We first tested evenly spaced thresholds for the number 364 of detected active infections up to 1% of the population, but later adopted thresholds that 365 were determined according to Equation 1. In Equation 1, D = population of state D at the 366 time of testing. T = number of active infections which, if reached, initiates everyday testing. The days between tests are rounded to the closest integer value. 367


368

Days between tests = max 
$$(1, 2\log_2(T/D) + 1)$$

369 (1)

370 The days between tests are chosen such that the detected active infections should 371 remain near to or below T. If the initial detected active infections are greater than T, then 372 the testing frequency of 1 will cause infections to rapidly drop. Both the threshold at which 373 everyday testing begins and the coefficient of  $log_2T/D$  can be modified to produce a 374 strategy that is more or less frequent in testing or resource effective; a range of days 375 between tests from 14 days to 1 day are used (Fig. 5). A scan over different choices of T 376 is shown in the supplements to Figure 5; the threshold we choose in Figure 5 is 0.05% 377 because it is successful in curbing the outbreak within the time period we consider. While

378 these choices work for the epidemic in California at the point we start our simulations, 10
379 April, they do not necessarily reflect the most resource effective choices everywhere. Our
380 analysis could be redone to select the best strategy in other states or in the country as a
381 whole.



382

**Figure 5.** Effect of County Based Rapid Test Protocol (A) and Uniform qRT-PCR Protocol (B) on active infected detected population over time in California (CA). The legend denotes the thresholds at which testing frequency is determined, the testing frequencies, the percent of CA population under the strategy, and the cost per person per day.

**Figure Supplement 1.** Effect of County Based Rapid Testing strategy on COVID-19 outcomes in California.

**Figure Supplement 2.** Time series of the three fitted pieces of data Cumulative Cases, Daily Hospitalized, and Cumulative Deaths for each CA county receiving testing.

```
384 Using a rapid test with a sensitivity of 80% and specificity of 90%, the county-based
```

- testing with threshold 0.05% reduces the active infections from 0.94% to 0.0005%, while
- the uniform strategy with tests administered every 7 days results in double the number of
- 387 active infections (Fig. 5). As the threshold is reduced, the total cost increases while the

cumulative infections, maximum percentage hospitalized, and cumulative deaths all
 decrease (Figure 5 - Figure Supplement 1).

390 Strategy B in Figure 5 consists of gRT-PCR testing uniformly applied to the 391 highlighted population with a frequency of once weekly. The average cost per person per 392 day is just under \$15. Despite this frequency and the accuracy of gRT-PCR, the strategy 393 does not succeed in curbing the spread as fast as strategy A, which uses a testing 394 sensitivity and specificity of 80% and 90%, respectively, and testing frequency that vary between counties depending on the proportion of their population that is currently 395 396 infected. The total cost for strategy A is estimated at a fraction of the other at \$1.53 per 397 person per day.

398

399

#### 400 **DISCUSSION**

401 In this study we examine the potential effects of a novel testing strategy to limit the 402 spread of SARS-CoV-2 utilizing rapid antigen test screening approaches. Our clinical data 403 and SIDHRE-Q modeling system demonstrate that 1) frequent rapid testing even at a 404 range of accuracies is effective at reducing COVID-19 spread, 2) rapid antigen tests are 405 a viable source for this strategy and diagnose the most infectious individuals, and 3) 406 strategic geographic-based testing can optimize disease control with the amount of 407 available resources. The information from a diagnostic test itself is of tremendous value, 408 as it can prompt the necessary guarantine measures to prevent spread, guide proper care 409 and triage, and provide crucial disease-tracking information. Diagnostic testing in the 410 United States and abroad, however, has been a significant public health hurdle. The 411 public has witnessed and experienced symptomatic individuals being denied testing due to shortages, and few testing structures for asymptomatic or mildly symptomatic individuals - the main source of disease spread. Though several factors contributed to the stymied early response measures, such as lockdown and quarantine protocols and adherence, severe testing bottlenecks were a significant culprit<sup>34–36</sup>. Early control measures have been shown to decrease lives lost by several orders of magnitude<sup>37</sup>. These challenges, though exacerbated during the early months of the pandemic, remain at the forefront of the public health crises.

419 Diagnosis of SARS-CoV-2 infection by qRT-PCR is the current standard of care, 420 yet remains expensive and requires a laboratory and experienced personnel for sample 421 preparations and experimentation. Significantly, the turnaround time for results can be up 422 to 10 days<sup>38</sup>. On an individual scale, this leaves the public in limbo, preventing people 423 from either leaving guarantine if they are negative, or delaying critical care and infecting 424 others if they are positive. On a societal level, this current testing scheme yields 425 incomplete surveillance data on which response efforts such as societal reopening and 426 hospital management depend. Though gRT-PCR is considered the gold-standard 427 diagnostic method because of its high sensitivity and specificity, the logistical hurdles 428 render it unrealistic for large-scale screening.

As qRT-PCR remains impractical for this strategy, and rapid tests are facing regulatory challenges because they do not perform with qRT-PCR-like accuracy, rapid test screening is either nonexistent in several countries or symptom-based. Even under best-case assumptions, findings have shown that symptom and risk-based screening strategies miss more than half of the infected individuals<sup>39</sup>. Some have argued that the need for widespread testing is overstated due to the variability in test sensitivity and

specificity<sup>40</sup>. Our findings show, however, that test performance, though valuable, is
secondary to widespread test frequency, which is enabled by accessibility and turnaround
time.

Giordano et al. has modeled the evolution of SARS-CoV-2 spread, introducing a 438 439 diagnosed state to elucidate the importance of population-wide testing<sup>16</sup>. Mina et al. has 440 examined how various test sensitivities and frequencies affect the reproductive number<sup>12</sup>. We build upon these findings to show how in affected United States and Brazil regions. 441 442 population-wide frequent and rapid testing schemes, with sensitivities ranging from 30%-443 90%, can be more effective in curbing the pandemic than a PCR-based scheme. 444 Integrating real-world surveillance and clinical data into our modeling system has allowed 445 us to incorporate regional differences - such as variances in healthcare access, state 446 health policy and adherence, state GDP, and environmental factors - under the same 447 model. Significantly, our findings hold true across Massachusetts, New York City, Los 448 Angeles, and São José do Rio Preto, Brazil. We also present the economic 449 considerations of these testing regimes, showing that widespread rapid testing is more 450 cost efficient than less frequent gRT-PCR testing. In line with these economic 451 considerations, our model demonstrates the effectiveness of a geographic-based 452 frequent testing regime, in which high disease prevalence areas receive more frequent 453 testing than low disease prevalence areas.

454 Since COVID-19 is known to affect certain demographics differently, modeling 455 would benefit from incorporating demographic information correlated with disease 456 progression and spread to define sub-models and sets of parameters accordingly. Age, 457 pre-existing conditions, job types, and density of population are examples of possible

458 categories, each of which influence the risk of contracting and/or dying from COVID-19.
459 Further studies may benefit from incorporating these ideas should more information
460 become available.

461 Our findings also point to low-cost tools for implementation of this testing strategy, 462 such as a rapid antigen-based test for the detection of SARS-CoV-2 proteins. We show 463 that the rapid antigen test performs with a range of accuracies under which disease spread can be dramatically mitigated under our model. Notably, the sensitivity is 464 correlated to the individual's viral load, effectively diagnosing those who are most 465 466 infectious with the highest accuracy. Our findings are significant because these rapid 467 antigen tests are cheaper than qRT-PCR, can be mass produced to millions per day, 468 present results within 15 minutes, and can be administered by a nonexpert without a lab 469 or special equipment.

There are several policy implications for these findings. First, our model supports 470 that systems of high frequency rapid testing should be implemented as a first-line 471 472 screening method. This can be first enabled by a more holistic regulatory evaluation of 473 rapid diagnostics, such that policy emphasizes accessibility and turnaround time even 474 under a range of accuracies. One can imagine a less accurate, though rapid method of 475 first-line screening in schools, public transportation, and airports, or even at home, and a 476 qRT-PCR-based method for second-line screening (testing those who present severe 477 symptoms or have been in contact with infected individuals, testing in a clinical setting, 478 etc). Second, our cost analysis and rapid antigen test data present a viable and potentially 479 more cost-effective method for screening. Third, our county-based testing scheme 480 presents a possible method for wide-scale screening while optimizing resources. Future

481 studies should investigate how this selective testing strategy can be applied to different 482 location scales to further inform health policy. Moreover, though our models analyze 483 regions in the United States and Brazil, similar testing strategies can be considered 484 globally in both resource limited and abundant settings due to the higher accessibility of 485 rapid tests compared to qRT-PCR.

486 We emphasize that integral to the effectiveness of diagnostic schemes is 1) the 487 proper adherence to quarantine measures and 2) the combined use of a variety of diagnostic methods including nucleic acid, antigen, and antibody tests. According to these 488 489 models, rapid antigen tests are an ideal tool for first-line screening. Clinical molecular 490 tests such as gRT-PCR are vital to the diagnostic landscape, particularly to re-test 491 suspected cases that were negative on the rapid test. Because rapid tests present a 492 higher rate of false negatives, methods such as qRT-PCR remain integral to second-line 493 screening. Antibody tests provide important information for immunity and vaccination 494 purposes as well as epidemiological surveillance. This model also assumes that 495 individuals will guarantine themselves before being tested and for 14 days following a 496 positive diagnostic result.

Our simulations combined with real-world data demonstrate a robust modeling system and elucidates the significance of this novel testing strategy. However, there are important limitations to be considered. Differences in disease reporting between the geographical regions and the incomplete nature of COVID-19 surveillance data, often due to the lack of testing, are not considered in the model. It is imperative that the testing results, hospitalization and death statistics, and changes in protocol are reported in realtime to scientists and policy makers so that models can be accurately tuned as the

504 pandemic develops. The model also does not take into account infrastructural limitations 505 such as hospital capacity. Though the rapid antigen test offers several advantages such 506 as affordability, fast turnaround time, and ease of mass production, we are also assuming 507 that there are systems in place to implement frequent and safe low-cost screening across 508 different communities and settings.

509 Our model underscores the need for a point-of-care or at-home test for frequent 510 screening, particularly as lockdown restrictions ease. Regulatory agencies such as the 511 FDA could work towards regulating rapid tests to alternative standards other than 512 comparison to high sensitivity molecular diagnostics, as our model shows that frequency 513 and scale of testing may overcome lower sensitivities. Rather, we could refocus policy to 514 implement first-line screening that optimizes accuracy with efficiency and equitability.

515

#### 516 MATERIAL AND METHODS

#### 517 Development of Direct Antigen Rapid Test for the Detection of SARS-CoV-2

518 We developed a direct antigen rapid test for the detection of the spike glycoprotein 519 from SARS-CoV-2 in nasopharyngeal swab specimens as previously described<sup>41</sup>. Briefly, 520 the rapid antigen test is an immunochromatographic format with a visual readout using 521 anti-spike mouse monoclonal antibodies (E25Bio, Inc., Cambridge, MA, USA) that are 522 either coupled to 40 nm gold nanoparticles (Abcam, Cambridge, UK) or adsorbed to 523 nitrocellulose membranes (Sartorius, Goettingen, Germany). Each rapid antigen test has 524 a control area adjacent to the paper absorbent pad; the control is an anti-mouse Fc 525 domain antibody (Leinco Technologies, Fenton, MO, USA) that will capture any of the 526 antibody-conjugated gold nanoparticles to generate a control visual signal. A visual signal

at the test area reflects SARS-CoV-2 spike glycoprotein that is "sandwiched" between an
anti-spike glycoprotein antibody adsorbed to the nitrocellulose membrane and a second
anti-spike glycoprotein antibody covalently coupled to visible gold nanoparticles.

530

# 531 Validation of Direct Antigen Rapid Test for the Detection of SARS-CoV-2

532 In a retrospective study of nasopharyngeal swab specimens from human patients, 533 we compared the accuracy of the rapid antigen test to the viral load of individuals. 534 Nasopharyngeal swab specimens (n = 121) were tested in Brazil following approved 535 human subjects use protocols. The age of study participants ranged from 1 to 95 years 536 with an overall median of 37 years (interguartile range, 27-51 years), and 62% were 537 female. The demographic summary of the patients are included in Supplementary Table 538 1. The nasopharyngeal swab specimens were banked refrigerated or frozen samples 539 from suspected patients submitted to the lab for routine COVID diagnosis. Prior to using the rapid test, the nasopharyngeal swab samples were validated by qRT-PCR using 540 541 GeneFinder<sup>TM</sup> COVID-19 Plus RealAmp Kit (OSANGHealtcare, Anyang-si, Gyeonggi-do, 542 Republic of Korea I). The primary study under which the samples and data were collected 543 received ethical clearance from the Faculdade de Medicina de São José do Rio Preto (FAMERP), protocol number 31588920.0.0000.5415. All excess samples and 544 545 corresponding data were banked and de-identified prior to the analyses.

546 A nasopharyngeal swab specimen (1 mL) was concentrated using a Vivaspin 500 547 centrifugal concentrator (Sartorius, Goettingen, Germany) at 12,000 x g for 10 minutes. 548 The concentrated nasopharyngeal swab specimen retentate was transferred to a 549 collection tube and the rapid antigen test was inserted into the tube with the retentate and

allowed to react for 15 minutes. After processing of the rapid antigen test, the visualpositive or negative signal was documented.

552

# 553 Data for Modeling

554 As of August 2020, the United States and Brazil have the highest number of 555 confirmed COVID-19 cases and deaths worldwide, with both countries reporting their first case on 26 February 2020<sup>1</sup>. Although several affected US regions could have been 556 modeled, we look at data from Massachusetts, New York, and Los Angeles: these regions 557 558 each contained "hotspots", or areas of surging COVID-19 cases, at different points in time 559 during the pandemic and have publicly available government-provided surveillance data. Our model is fit using data over 105 days beginning on April 1 for Figures 3 and 4 and 560 105 days beginning on April 10 for Figure 5 (see "Modeling Parameters" in Methods). In 561 order to understand the various testing proposals on a global scale, we performed our 562 563 clinical study in and expanded the modeling study to Brazil. The specific data we use to 564 fit our model are cumulative confirmed cases, total deaths, and number of daily 565 hospitalizations due to COVID-19. This surveillance data was retrieved from governmentprovided online databases<sup>42-48</sup>. 566

567

#### 568 Modeling Parameters

569 Equation 2 below provides the exact differential equations governing the model.

$\mathrm{d}\mathbf{S} =$	$-\mathbf{S}\left(lpha\mathbf{I}+\eta\mathbf{D}+\gamma ight)$	$+\psi \mathbf{Q}_{\mathbf{U}}$
$\mathrm{d}\mathbf{I} =$	$- \mathbf{I} \left( \varepsilon + \lambda + \nu \right)$	$+ \mathbf{S} \left( \alpha \mathbf{I} + \eta \mathbf{D} \right)$
$\mathrm{d}\mathbf{D} =$	$-  \mathbf{D} \left( rac{\mathbf{D} + \mathbf{I}}{\mathbf{D}} \mu +  ho  ight)$	$+ \mathbf{I}( u + arepsilon)$
$\mathrm{d}\mathbf{H} =$	$-\mathbf{H}\left(\sigma+ au ight)$	$+ \mu \left( \mathbf{D} + \mathbf{I}  ight)$
$\mathrm{d}\mathbf{E} =$		$+  au \mathbf{H}$
$\mathrm{d}\mathbf{R} =$	$-\gamma \mathbf{R}$	$+ \rho \mathbf{D} + \lambda \mathbf{I} + \sigma \mathbf{H} + \psi \mathbf{Q_R}$
$\mathrm{d}\mathbf{Q}_{\mathbf{U}} =$	$-\psi {f Q}_{f U}$	$+ \gamma S$
$\mathrm{d}\mathbf{Q}_{\mathbf{R}} =$	$-\psi \mathbf{Q_R}$	$+ \gamma \mathbf{R}$
		(2)

570

571 In order to determine the values of the parameters defining the flows between states, we 572 use a least squares regression performed at seven day intervals in the datasets to which 573 we fit. This allows the model to take into account the time dependent nature of the 574 parameters, which rely on factors such as social distancing regulations and changes in 575 testing capacity. We also fit window sizes between 1 and 21 days and find that while the 576 fit degrades with larger window size, the overall shape of the fits do not change. We choose seven days assuming policy changes take a week to become effective and that 577 578 reasonable parameters can be expected to change within this time period. Also, the seven 579 day window size accounts for the fact that often data is not reported as diligently over the 580 weekend. Time series of the values of the parameters for the geographic locations 581 discussed in this paper can be found in the supplemental materials for Figure 2.

582 Given the restrictions on data available for the populations of various states, 583 varying all of the parameters results in an over parameterized system. Therefore, a subset 584 of the model parameters are fit while the others are either extracted from other sources; 585 see Table 5.

586

# 588 **Table 5.** Details of parameter values used for *SIDHRE-Q* Model.

Parameter	Details & Statistics			
α	$\alpha$ is the probability that an interaction between an undetected infected person and an uninfected person results in a new infection, divided by the		Mean	St. Dev.
	average number of uninfected people an undetected infected person comes into contact with on a given day. $\alpha$ is estimated from the data.	MA	0.088	0.051
		LA	0.090	0.034
		NYC	0.067	0.042
		SJRP	0.121	0.042
η	$\eta$ is the probability that an interaction between an infected person and an ur a new infection, divided by the average number of uninfected people a comes into contact with on a given day. $\eta = 0.01 \cdot \alpha$ The constant relating $\eta$ , $\alpha$ accounts for a small but nonzero transmission (detected) infected population. This value was chosen to be small, assumin will only infect others with low probability.	detecteo n due to	the qua	d person arantine
ν	$\nu$ is the probability that a symptomatic undetected individual is diagnosed		Mean	St. Dev.
	on a given day. $\nu$ is estimated from the data. $\nu$ is multiplied by sensitivity (assume benchmark sensitivity 100% for PCR, as used when fitting).	MA	0.006	0.005
		LA	0.011	0.006
		NYC	0.0056	0.002
		SJRP	0.015	0.007
E	$\epsilon$ is the probability that an asymptomatic undetected infected individual is $\epsilon = 0$ while fitting (during PCR symptomatic testing). $\epsilon =$ (sensitivity/days rapid testing strategy is activated.	-	-	-
λ	$\lambda$ is the probability that an undetected infected individual transitions to the reday. $\lambda = 1/14$ , or the inverse of average recovery time. <sup>48</sup>	ecovered	d state or	n a give
μ	$\mu$ is the probability that an infected individual develops severe symptoms on a given day and transitions into the hospitalized state. The flow from <i>D</i>		Mean	St. Dev
	to <i>H</i> is assumed to be independent of the ratio $I/D$ , but comes only from the detected infected population, hence why it is multiplied by $(I + D)/D$ . $\mu$ is estimated from the data.	MA	0.0013	9.5e-4
		LA	0.0016	2.4e-4
		NYC	0.0011	6.6e-4
		SJRP	0.0018	8.0e-4
ρ	ho is the probability that a detected infected individual transitions to the recov	ered stat	te on a gi	ven da
	ho = 1/14, or the inverse of the average recovery time. <sup>48</sup>			

σ	$\sigma$ is the probability that a hospitalized individual transitions to the recovered state on a given day. $\sigma = 1/11$ , or the inverse of the average recovery time for a hospitalized individual. <sup>48</sup>									
τ	au is the probability that a hospitalized individual expires on a given day. $ au$ is estimated from the data.		Mean	St. Dev.						
			0.034	0.012						
			0.016	0.004						
		NYC	0.036	0.034						
		SJRP	0.032	0.045						
γ	$\gamma$ is the probability of entering either of the quarantine states on a given day from either the Susceptible or Recovered populations. $\gamma = 0$ while fitting (during PCR symptomatic testing). $\gamma = (1 - \text{specificity}) \times (1/\text{days between tests})$ when the rapid testing strategy is activated.									
ψ	$\psi$ is the probability that an individual exits quarantine on a given day. $\psi = 1/14$ , or the inverse of the quarantine period for fixed length quarantine.									

589

The fitting procedure minimizes the sum of the squared residuals of the total cases, 590 591 current daily hospitalizations, cumulative deaths, and percentage of total infected individuals currently hospitalized. The first three are present in the data sets while the 592 593 latter is derived from the estimates of the ratio between infected undetected to infected 594 detected individuals from the CDC Laboratory Seroprevalence Survey Data<sup>49</sup>. While this 595 ratio changes over time, the percentage of infected individuals developing severe 596 symptoms should remain roughly constant throughout the course of the epidemic in the 597 different locations studied.

We consider the data sets for outbreaks in MA, NYC, LA, and SJRP, Brazil<sup>42–47</sup>. While each location has testing and fatality information dating back to January, hospitalization data was not included until late March (for NYC and SJRP) and April (for MA and LA). Hence we begin our fitting procedure and testing strategy on 1 April for each of the data sets; by this point, the outbreak is advanced in NYC, substantial in MA, non-negligible, but far from its peak, in LA, and in early stages in SJRP, Brazil. Starting

simulations at various stages of the outbreak allows one to see the difference in resultsbetween when a testing strategy is administered.

606 In order to determine the effectiveness of the county-based strategy when applied 607 to the state of California, we also fit all of the counties in California with a population 608 greater than 1.5% of that of the entire state and with greater than zero deaths. The results 609 do not depend on these selections, but instead suggest a practical criteria to administer 610 limited resources. The fitting is done starting 10 April for these counties, as at this point 611 the outbreak is sufficiently well-documented in each to successfully model. For the 612 county-level data we compute a seven day running average of each of the data sets to 613 which we then fit in order to smooth out fluctuations in the data, likely due to reporting, 614 which are more significant here than in the other data sets considered, as the county 615 populations are smaller and hence discrepancies impact the smoothness of the data 616 more. The fits for each of the counties can be found in the supplementary materials to 617 Figure 5.

As one can see from Figure 2, these data sets are particularly not smooth, which indicates inefficiencies in reporting. Additionally, it is difficult to gauge their consistency within the dates provided or to compare between locations, as reporting mechanisms changed over time within the same locations. Despite this lack of consistency, our model and fitting mechanism was successful in reproducing the progress of the outbreak in each data set studied.

The authors confirm that the data supporting the findings of this study are available within the article and/or its supplementary materials; any other data will be made available upon request. Our code can be found on github:

- 627 <u>https://github.com/badeaa3/COVID19\_Rapid\_Testing</u>. The code is written using python
  628 with the packages scipy, numpy, Imfit, matplotlib and plotly<sup>50–54</sup>.
- 629

# 630 Acknowledgments

631 We thank Professor Lee Gehrke for critical reading of the manuscript. The study is 632 funded, in part, by a Bill and Melinda Gates Foundation Award (INV-017872) to E25Bio, 633 Inc. EN is funded by Tufts University DISC Seed Grant. MLN is supported by a FAPESP 634 grant (#2020/04836-0) and is a CNPq Research Fellow. AFV is supported by a FAPESP 635 Fellow grant (#18/17647-0). GRFC is supported by a FAPESP Fellow grant (#20/07419-636 0). BHGAM is supported by a FAPESP Scholarship (#19/06572-2). The funders had no 637 role in the design of the study; in the collection, analyses, or interpretation of data; in the 638 writing of the manuscript, or in the decision to publish the results.

639

#### 640 Competing Interest

641 BN, AB, AR, MB, NS, AG, IB, and BBH are employed by or affiliated with E25Bio 642 Inc. (www.e25bio.com), a company that develops diagnostics for epidemic viruses.

643

#### 644 **References**

- 645 1. Coronavirus Disease (COVID-19) Situation Reports.
  646 https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.
- 647 2. Menkir, T. F. *et al.* Estimating the number of undetected COVID-19 cases exported
  648 internationally from all of China. *medRxiv* (2020) doi:10.1101/2020.03.23.20038331.
- 649 3. Ivorra, B., Ferrández, M. R., Vela-Pérez, M. & Ramos, A. M. Mathematical modeling of the
  650 spread of the coronavirus disease 2019 (COVID-19) taking into account the undetected

- 651 infections. The case of China. *Commun Nonlinear Sci Numer Simul* 105303 (2020)
  652 doi:10.1016/j.cnsns.2020.105303.
- 4. Salathé, M. *et al.* COVID-19 epidemic in Switzerland: on the importance of testing, contact
  tracing and isolation. *Swiss Med Wkly* **150**, w20225 (2020).
- Lau, H. *et al.* Evaluating the massive underreporting and undertesting of COVID-19 cases in
   multiple global epicenters. *Pulmonology* (2020) doi:10.1016/j.pulmoe.2020.05.015.
- 6. Silverman, J. D., Hupert, N. & Washburne, A. D. Using influenza surveillance networks to
   estimate state-specific prevalence of SARS-CoV-2 in the United States. *Science Translational Medicine* (2020) doi:10.1126/scitranslmed.abc1126.
- 660 7. Böhning, D., Rocchetti, I., Maruotti, A. & Holling, H. Estimating the undetected infections in
  661 the Covid-19 outbreak by harnessing capture-recapture methods. *Int. J. Infect. Dis.* 97, 197–
  662 201 (2020).
- 8. Baek, Y. H. *et al.* Development of a reverse transcription-loop-mediated isothermal
  amplification as a rapid early-detection method for novel SARS-CoV-2. *Emerg Microbes Infect*9, 998–1007 (2020).
- 666 9. Leo, L. Mylab gets commercial approval from ICMR for Covid-19 antigen rapid testing kit.
- 667 *Livemint* https://www.livemint.com/news/india/mylab-gets-commercial-approval-from-icmr-668 for-covid-19-antigen-rapid-testing-kit-11595434040321.html (2020).
- 10. Dey, S. Coronavirus testing: Rapid antigen tests now make up nearly half of daily checks |
- 670 India News Times of India. The Times of India
- 671 https://timesofindia.indiatimes.com/india/rapid-antigen-tests-now-make-up-nearly-half-of-
- daily-checks/articleshow/77340459.cms.
- 11. Vogels, C. B. F. et al. Analytical sensitivity and efficiency comparisons of SARS-CoV-2 RT-
- 674 qPCR primer-probe sets. *Nat Microbiol* (2020) doi:10.1038/s41564-020-0761-6.
- 12. Larremore, D. B. et al. Test sensitivity is secondary to frequency and turnaround time for
- 676 COVID-19 surveillance. *medRxiv* (2020) doi:10.1101/2020.06.22.20136309.

- 677 13. Shen, Z. *et al.* Superspreading SARS events, Beijing, 2003. *Emerging Infect. Dis.* **10**, 256–
  678 260 (2004).
- 14. Peiris, J. S. M. *et al.* Clinical progression and viral load in a community outbreak of
  coronavirus-associated SARS pneumonia: a prospective study. *Lancet* 361, 1767–1772
  (2003).
- 15. He, X. *et al.* Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nat. Med.*26, 672–675 (2020).
- 684 16. Giordano, G. *et al.* Modelling the COVID-19 epidemic and implementation of population-wide
  685 interventions in Italy. *Nat. Med.* 26, 855–860 (2020).
- 686 17. Choi, S. & Ki, M. Estimating the reproductive number and the outbreak size of COVID-19 in
- 687 Korea. *Epidemiol Health* **42**, e2020011 (2020).
- 18. Wei, Y. Y. *et al.* [Fitting and forecasting the trend of COVID-19 by SEIR(+CAQ) dynamic
  model]. *Zhonghua Liu Xing Bing Xue Za Zhi* 41, 470–475 (2020).
- 490 19. Yang, Z. *et al.* Modified SEIR and AI prediction of the epidemics trend of COVID-19 in China
  491 under public health interventions. *J Thorac Dis* **12**, 165–174 (2020).
- 692 20. Cao, S., Feng, P. & Shi, P. [Study on the epidemic development of COVID-19 in Hubei
  693 province by a modified SEIR model]. *Zhejiang Da Xue Xue Bao Yi Xue Ban* 49, 178–184
  694 (2020).
- 695 21. Huang, R., Liu, M. & Ding, Y. Spatial-temporal distribution of COVID-19 in China and its
  696 prediction: A data-driven modeling analysis. *J Infect Dev Ctries* 14, 246–253 (2020).
- 22. Godio, A., Pace, F. & Vergnano, A. SEIR Modeling of the Italian Epidemic of SARS-CoV-2
- Using Computational Swarm Intelligence. *Int J Environ Res Public Health* **17**, (2020).
- 699 23. Gatto, M. *et al.* Spread and dynamics of the COVID-19 epidemic in Italy: Effects of emergency
- 700 containment measures. Proc. Natl. Acad. Sci. U.S.A. 117, 10484–10491 (2020).
- 701 24. Hou, C. *et al.* The effectiveness of quarantine of Wuhan city against the Corona Virus Disease
- 702 2019 (COVID-19): A well-mixed SEIR model analysis. J. Med. Virol. 92, 841–848 (2020).

- Zhou, T. *et al.* Preliminary prediction of the basic reproduction number of the Wuhan novel
  coronavirus 2019-nCoV. *J Evid Based Med* 13, 3–7 (2020).
- 26. Reno, C. et al. Forecasting COVID-19-Associated Hospitalizations under Different Levels of
- 706 Social Distancing in Lombardy and Emilia-Romagna, Northern Italy: Results from an
- 707 Extended SEIR Compartmental Model. *J Clin Med* **9**, (2020).
- 708 27. Alizargar, J. Risk of reactivation or reinfection of novel coronavirus (COVID-19). J. Formos.
- 709 *Med. Assoc.* **119**, 1123 (2020).
- 710 28. Batisse, D. et al. Clinical recurrences of COVID-19 symptoms after recovery: viral relapse,
- reinfection or inflammatory rebound? J. Infect. (2020) doi:10.1016/j.jinf.2020.06.073.
- 712 29. Deng, W. et al. Primary exposure to SARS-CoV-2 protects against reinfection in rhesus
- 713 macaques. *Science* (2020) doi:10.1126/science.abc5343.
- 30. Ota, M. Will we see protection or reinfection in COVID-19? *Nat. Rev. Immunol.* **20**, 351 (2020).
- 715 31. Victor Okhuese, A. Estimation of the Probability of Reinfection With COVID-19 by the
- 716 Susceptible-Exposed-Infectious-Removed-Undetectable-Susceptible Model. JMIR Public
- 717 *Health Surveill* **6**, e19097 (2020).
- 32. Gu, Y. COVID-19 Projections Using Machine Learning. COVID-19 Projections Using Machine
   *Learning* https://covid19-projections.com/.
- 33. Stadlbauer, D. *et al.* Seroconversion of a city: Longitudinal monitoring of SARS-CoV-2
  seroprevalence in New York City. *medRxiv* 2020.06.28.20142190 (2020)
  doi:10.1101/2020.06.28.20142190.
- 34. Goodnough, A. & Shear, M. D. The U.S.'s Slow Start to Coronavirus Testing: A Timeline. *The New York Times* (2020).
- 35. Shear, M. D. *et al.* The Lost Month: How a Failure to Test Blinded the U.S. to Covid-19. *The New York Times* (2020).
- 36. Kaplan, S. & Thomas, K. Despite Promises, Testing Delays Leave Americans 'Flying Blind'. *The New York Times* (2020).

- 37. de Souza, W. M. *et al.* Epidemiological and clinical characteristics of the COVID-19 epidemic
  in Brazil. *Nature Human Behaviour* 4, 856–865 (2020).
- 38. Mervosh, S. & Fernandez, M. 'It's Like Having No Testing': Coronavirus Test Results Are Still
  Delayed. *The New York Times* (2020).
- 39. Gostic, K., Gomez, A. C., Mummah, R. O., Kucharski, A. J. & Lloyd-Smith, J. O. Estimated
  effectiveness of symptom and risk screening to prevent the spread of COVID-19. *eLife* 9,
  e55570 (2020).
- 736 40. Zitek, T. The Appropriate Use of Testing for COVID-19. *West J Emerg Med* 21, 470–472
  737 (2020).
- 41. Bosch, I. *et al.* Rapid antigen tests for dengue virus serotypes and Zika virus in patient serum.
- 739 Sci Transl Med **9**, (2017).
- 42. Massachusetts Department of Public Health. COVID-19 Response Reporting. *Mass.gov*https://www.mass.gov/info-details/covid-19-response-reporting.
- 742 43. California Department of Public Health. COVID-19 Cases California Open Data.
  743 https://data.ca.gov/dataset/covid-19-cases.
- 44. California Department of Public Health. COVID-19 Hospital Data California Open Data.
  https://data.ca.gov/dataset/covid-19-hospital-data.
- 746 45. Department of Health and Human Hygiene. COVID-19 Daily Counts of Cases,
  747 Hospitalizations, and Deaths | NYC Open Data. https://data.cityofnewyork.us/Health/COVID-
- 748 19-Daily-Counts-of-Cases-Hospitalizations-an/rc75-m7u3.
- 46. Sao Jose do Rio Preto Public Health Office. *COVID-19 Surveillance Data, Sao Jose do Rio Preto.*
- 47. New York State Government. Daily Hospitalization Summary by Region. *New York Forward*https://forward.ny.gov/daily-hospitalization-summary-region.
- 48. Massachusetts General Hospital Institute for Technology Assessment. COVID-19 Simulator
- 754 Methodology. https://www.covid19sim.org/images/docs/COVID-

- 755 19\_simulator\_methodology\_download\_20200507.pdf.
- 49. CDC. Coronavirus Disease 2019 (COVID-19). Centers for Disease Control and Prevention
- 757 https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-lab-surveys.html
- 758 (2020).
- 50. SciPy.org SciPy.org. https://www.scipy.org/.
- 760 51. NumPy. https://numpy.org/.
- 761 52. Non-Linear Least-Squares Minimization and Curve-Fitting for Python Non-Linear Least-
- 762 Squares Minimization and Curve-Fitting for Python. https://lmfit.github.io/lmfit-py/.
- 53. Matplotlib: Python plotting Matplotlib 3.3.1 documentation. https://matplotlib.org/.
- 54. Plotly: The front-end for ML and data science models. <u>https://plotly.com/</u>.